Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, Goss TF. Development and validation of the ITG Health-Related Quality-of- Life Short-Form measure for use in patients with coronary artery disease. Integrated Therapeutics Group. Clin Cardiol. 2001 Aug;24(8):556-63.
Brotons C, Rivero E, Perich RM. Hypercholesterolemia in childhood and adolescence. Fmc - Formacion Medica. 1994;4:231-7.